Personalized circulating tumor DNA analysis to monitor colorectal cancer AACR 2018

July 28, 2021

Early detection of disease recurrence has been shown to improve survival in patients with colorectal cancer (CRC); detection of circulating tumor DNA (ctDNA).

Download PDF

Personalized circulating tumor DNA analysis to monitor colorectal cancer AACR 2018

Utility of ctDNA in assessment of treatment response in patients with Recurrent/Metastatic Endometrial Cancer and Recurrent/Platinum-Resista

Personalized circulating tumor DNA analysis used for ctDNA detection and response monitoring in patients with advanced or recurrent uterine

PARPi response monitoring using personalized circulating tumor DNA testing in patients with ovarian cancer

Treatment Monitoring Utilizing ctDNA-based Molecular Residual Disease Detection in Early Stage Uterine Cancer

Utility of ctDNA as an Early Predictive Biomarker of Response to RT/CRT in Gynecologic Malignancies

Prognostic implications of minimal residual disease detection by second look laparoscopy and circulating tumor DNA in patients with ovarian

Diagnostic yield and characteristics of germline-positive genetic testing ordered by obstetricians and gynecologists in female patients with

Utility of circulating tumor DNA (ctDNA) for the detection of minimal residual disease (MRD) after curative-intent therapy for patients with

The role of pre-operative ctDNA in resectable intrahepatic cholangiocarcinoma

Association of circulating tumor DNA (ctDNA) molecular disease (MRD) detection with lymph node metastasis after local excision of pathologic

Prediction of postoperative recurrence by integrating preoperative ctDNA levels and tumor metastasis volume in patients with colorectal canc

INTERCEPT Program of Circulating Tumor DNA (ctDNA) Testing for Minimal ResidualDisease (MRD) in Colorectal Cancer (CRC): Results from a Pros

Patient-reported outcomes from the BESPOKE CRC study

A Phase II Trial of TAS-102 in Colorectal Cancer Patients with ctDNA-defined Minimal Residual Disease Post-Adjuvant Therapy: Results from th

Prognostic value of circulating tumor DNA (ctDNA) testing in rectal cancer patients (pts) after neoadjuvant therapy (NAT) and surgery

Personalized ctDNA testing for detection of molecular residual disease in patients with localized HR+ breast cancer: Temporal dynamics...

Results from a pilot study exploring ctDNA detection using a tumor-informed assay in the monarchE trial of adjuvant abemaciclib with endocri

Circulating tumor DNA (ctDNA) monitoring of estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) high r

Personalized circulating tumor DNA testing for detection of progression and treatment response monitoring in patients with metastatic invasi

Personalized circulating tumor DNA monitoring to predict response to neoadjuvant therapy in patients with early-stage breast cancer